PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

NCT07028424 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

206

Enrollment

OTHER

Sponsor class

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Nal-IRI
DRUG: Ciprofloxacin
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: 5-Fluorouracil
OTHER: Placebo

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

[object Object]